Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis
A maternal RSV vaccination program in Australia could provide value for money by reducing hospitalisations and associated costs among infants aged <6 months, depending on the vaccine price. We have provided evidence that herd effects beyond the target population may be an important consideration in assessing cost-effectiveness of maternal RSV vaccination.
Authors
- James Wood (ORCID: https://orcid.org/0000-0002-0122-4482)
- Nusrat Homaira (ORCID: https://orcid.org/0000-0003-3341-7964)
- Allen L. Nazareno (ORCID: https://orcid.org/0000-0002-8969-6774)
- Anthony T. Newall (ORCID: https://orcid.org/0000-0003-0836-1065)
- Alexandra B. Hogan (ORCID: https://orcid.org/0000-0002-6271-9921)
- David Muscatello (ORCID: https://orcid.org/0000-0002-2391-4396)
Institutions
- UNSW Sydney (AU)
Publication Details
- Journal
- Vaccine
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1016/j.vaccine.2024.126651
- Citations
- 4
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 1.55
Funders
- National Health and Medical Research Council